Literature DB >> 23229893

SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases.

Mathew B Wong1, Jacob Goodwin, Anwar Norazit, Adrian C B Meedeniya, Christiane Richter-Landsberg, Wei Ping Gai, Dean L Pountney.   

Abstract

Oligodendroglial inclusion bodies characterize a subset of neurodegenerative diseases. Multiple system atrophy (MSA) is characterized by α-synuclein glial cytoplasmic inclusions and progressive supranuclear palsy (PSP) is associated with glial tau inclusions. The ubiquitin homologue, SUMO-1, has been identified in inclusion bodies in MSA, located in discrete sub-domains in α-synuclein-positive inclusions. We investigated SUMO-1 associated with oligodendroglial inclusion bodies in brain tissue from MSA and PSP and in glial cell models. We examined MSA and PSP cases and compared to age-matched normal controls. Fluorescence immunohistochemistry revealed frequent SUMO-1 sub-domains within and surrounding inclusions bodies in both diseases and showed punctate co-localization of SUMO-1 and the lysosomal marker, cathepsin D, in affected brain regions. Cell counting data revealed that 70-75 % of lysosomes in inclusion body-positive oligodendrocytes were SUMO-1-positive consistently across MSA and PSP cases, compared to 20 % in neighbouring inclusion body negative oligodendrocytes and 10 % in normal brain tissue. Hsp90 co-localized with some SUMO-1 puncta. We examined the SUMO-1 status of lysosomes in 1321N1 human glioma cells over-expressing α-synuclein and in immortalized rat oligodendrocyte cells over-expressing the four repeat form of tau following treatment with the proteasome inhibitor, MG132. We also transfected 1321N1 cells with the inherently aggregation-prone huntingtin exon 1 mutant, HttQ74-GFP. Each cell model showed the association of SUMO-1-positive lysosomes around focal cytoplasmic accumulations of α-synuclein, tau or HttQ74-GFP, respectively. Association of SUMO-1 with lysosomes was also detected in glial cells bearing α-synuclein aggregates in a rotenone-lesioned rat model. SUMO-1 labelling of lysosomes showed a major increase between 24 and 48 h post-incubation of 1321N1 cells with MG132 resulting in an increase in a 90 kDa SUMO-1-positive band that was immunopositive for Hsp90 and immunoprecipitated with an anti-SUMO-1 antibody. That SUMO-1 co-localizes with a subset of lysosomes in neurodegenerative diseases with glial protein aggregates and in glial cell culture models of protein aggregation suggests a role for SUMO-1 in lysosome function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23229893     DOI: 10.1007/s12640-012-9358-z

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  64 in total

1.  Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.

Authors:  Anwar Norazit; Adrian C B Meedeniya; Maria Nga Nguyen; Alan Mackay-Sim
Journal:  Brain Res       Date:  2010-08-31       Impact factor: 3.252

Review 2.  SUMO on the road to neurodegeneration.

Authors:  Véronique Dorval; Paul E Fraser
Journal:  Biochim Biophys Acta       Date:  2007-03-30

3.  Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity.

Authors:  Preeti Putcha; Karin M Danzer; Lisa R Kranich; Anisa Scott; Melanie Silinski; Sarah Mabbett; Carol D Hicks; James M Veal; Paul M Steed; Bradley T Hyman; Pamela J McLean
Journal:  J Pharmacol Exp Ther       Date:  2009-11-24       Impact factor: 4.030

Review 4.  Recent developments in multiple system atrophy.

Authors:  Gregor K Wenning; Nadia Stefanova
Journal:  J Neurol       Date:  2009-05-27       Impact factor: 4.849

5.  NSF, Unc-18-1, dynamin-1 and HSP90 are inclusion body components in neuronal intranuclear inclusion disease identified by anti-SUMO-1-immunocapture.

Authors:  Dean L Pountney; Mark J Raftery; Fariba Chegini; Peter C Blumbergs; Wei Ping Gai
Journal:  Acta Neuropathol       Date:  2008-10-03       Impact factor: 17.088

Review 6.  Parkin-mediated ubiquitin signalling in aggresome formation and autophagy.

Authors:  Lih-Shen Chin; James A Olzmann; Lian Li
Journal:  Biochem Soc Trans       Date:  2010-02       Impact factor: 5.407

7.  A proteomic strategy for gaining insights into protein sumoylation in yeast.

Authors:  Carilee Denison; Adam D Rudner; Scott A Gerber; Corey E Bakalarski; Danesh Moazed; Steven P Gygi
Journal:  Mol Cell Proteomics       Date:  2004-11-12       Impact factor: 5.911

8.  Association of metallothionein-III with oligodendroglial cytoplasmic inclusions in multiple system atrophy.

Authors:  D L Pountney; T C Dickson; J H T Power; J C Vickers; A J West; W P Gai
Journal:  Neurotox Res       Date:  2009-12-29       Impact factor: 3.911

9.  Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini.

Authors:  Hui Ouyang; Yousuf O Ali; Mani Ravichandran; Aiping Dong; Wei Qiu; Farrell MacKenzie; Sirano Dhe-Paganon; Cheryl H Arrowsmith; R Grace Zhai
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

Review 10.  Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction.

Authors:  Stéphane Martin; Kevin A Wilkinson; Atsushi Nishimune; Jeremy M Henley
Journal:  Nat Rev Neurosci       Date:  2007-12       Impact factor: 34.870

View more
  20 in total

Review 1.  SUMOylation: Novel Neuroprotective Approach for Alzheimer's Disease?

Authors:  Juliana B Hoppe; Christianne G Salbego; Helena Cimarosti
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

2.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

3.  Sumo E2 enzyme UBC9 is required for efficient protein quality control in cardiomyocytes.

Authors:  Manish K Gupta; James Gulick; Ruijie Liu; Xuejun Wang; Jeffery D Molkentin; Jeffrey Robbins
Journal:  Circ Res       Date:  2014-08-05       Impact factor: 17.367

Review 4.  SUMO and Parkinson's disease.

Authors:  Katrin Eckermann
Journal:  Neuromolecular Med       Date:  2013-08-25       Impact factor: 3.843

Review 5.  Synthetic Proteins and Peptides for the Direct Interrogation of α-Synuclein Posttranslational Modifications.

Authors:  Matthew R Pratt; Tharindumala Abeywardana; Nicholas P Marotta
Journal:  Biomolecules       Date:  2015-06-25

Review 6.  Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer's Disease and Related Tauopathies.

Authors:  Christiana Kontaxi; Pedro Piccardo; Andrew C Gill
Journal:  Front Mol Biosci       Date:  2017-08-11

Review 7.  Multiple system atrophy: the application of genetics in understanding etiology.

Authors:  Monica Federoff; Lucia V Schottlaender; Henry Houlden; Andrew Singleton
Journal:  Clin Auton Res       Date:  2015-02-17       Impact factor: 4.435

Review 8.  Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity.

Authors:  Shamini Vijayakumaran; Mathew B Wong; Helma Antony; Dean L Pountney
Journal:  Biomolecules       Date:  2015-07-24

Review 9.  Neuroinflammation in Multiple System Atrophy: Response to and Cause of α-Synuclein Aggregation.

Authors:  Bruno Di Marco Vieira; Rowan A Radford; Roger S Chung; Gilles J Guillemin; Dean L Pountney
Journal:  Front Cell Neurosci       Date:  2015-11-12       Impact factor: 5.505

10.  Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy.

Authors:  Antonio Piras; Ludovic Collin; Fiona Grüninger; Caroline Graff; Annica Rönnbäck
Journal:  Acta Neuropathol Commun       Date:  2016-03-02       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.